208 related articles for article (PubMed ID: 18675828)
21. Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations.
Maeda H; Hazama S; Shavkat A; Okamoto K; Oba K; Sakamoto J; Takahashi K; Oka M; Nakamura D; Tsunedomi R; Okayama N; Mishima H; Kobayashi M
Mol Diagn Ther; 2014 Jun; 18(3):333-42. PubMed ID: 24453052
[TBL] [Abstract][Full Text] [Related]
22. Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer.
Bajro MH; Josifovski T; Panovski M; Jankulovski N; Nestorovska AK; Matevska N; Petrusevska N; Dimovski AJ
Cancer Genet; 2012 Apr; 205(4):163-7. PubMed ID: 22559977
[TBL] [Abstract][Full Text] [Related]
23. UDP-glucuronosyltransferase 1A1 (UGT1A1) gene haplotypes and their effect on serum bilirubin concentration in healthy Indian adults.
D'Silva S; Colah RB; Ghosh K; Mukherjee MB
Gene; 2013 Jan; 513(1):36-9. PubMed ID: 23147267
[TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and prostate cancer risk in Caucasian men.
Karatzas A; Giannatou E; Tzortzis V; Gravas S; Aravantinos E; Moutzouris G; Melekos M; Tsezou A
Cancer Epidemiol; 2010 Jun; 34(3):345-9. PubMed ID: 20308029
[TBL] [Abstract][Full Text] [Related]
25. UGT1A1(TA)n promoter polymorphism--a new case of a (TA)8 allele in Caucasians.
Ostanek B; Furlan D; Mavec T; Lukac-Bajalo J
Blood Cells Mol Dis; 2007; 38(2):78-82. PubMed ID: 17196409
[TBL] [Abstract][Full Text] [Related]
26. Red meat-derived heterocyclic amines increase risk of colon cancer: a population-based case-control study.
Helmus DS; Thompson CL; Zelenskiy S; Tucker TC; Li L
Nutr Cancer; 2013; 65(8):1141-50. PubMed ID: 24168237
[TBL] [Abstract][Full Text] [Related]
27. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk.
Goodman JE; Bowman ED; Chanock SJ; Alberg AJ; Harris CC
Carcinogenesis; 2004 Dec; 25(12):2467-72. PubMed ID: 15308583
[TBL] [Abstract][Full Text] [Related]
28. Lack of association between the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and the risk of benign prostatic hyperplasia in Caucasian men.
Karatzas A; Tzortzis V; Giannatou E; Gravas S; Zachos I; Oeconomou A; Melekos M; Tsezou A
Mol Biol Rep; 2013 Dec; 40(12):6665-9. PubMed ID: 24057187
[TBL] [Abstract][Full Text] [Related]
29. Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.
Sandanaraj E; Jada SR; Shu X; Lim R; Lee SC; Zhou Q; Zhou S; Goh BC; Chowbay B
Pharmacogenomics J; 2008 Jun; 8(3):174-85. PubMed ID: 17700594
[TBL] [Abstract][Full Text] [Related]
30. UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver.
Girard H; Thibaudeau J; Court MH; Fortier LC; Villeneuve L; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
Hepatology; 2005 Aug; 42(2):448-57. PubMed ID: 15986396
[TBL] [Abstract][Full Text] [Related]
31. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
Girard H; Villeneuve L; Court MH; Fortier LC; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
Drug Metab Dispos; 2006 Jul; 34(7):1220-8. PubMed ID: 16595709
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans.
Huo D; Kim HJ; Adebamowo CA; Ogundiran TO; Akang EE; Campbell O; Adenipekun A; Niu Q; Sveen L; Fackenthal JD; Fackenthal DL; Das S; Cox N; Di Rienzo A; Olopade OI
Breast Cancer Res Treat; 2008 Jul; 110(2):367-76. PubMed ID: 17909964
[TBL] [Abstract][Full Text] [Related]
33. Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant.
Fang JL; Lazarus P
Cancer Epidemiol Biomarkers Prev; 2004 Jan; 13(1):102-9. PubMed ID: 14744740
[TBL] [Abstract][Full Text] [Related]
34. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.
Girard H; Court MH; Bernard O; Fortier LC; Villeneuve L; Hao Q; Greenblatt DJ; von Moltke LL; Perussed L; Guillemette C
Pharmacogenetics; 2004 Aug; 14(8):501-15. PubMed ID: 15284532
[TBL] [Abstract][Full Text] [Related]
35. Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels.
Guillemette C; De Vivo I; Hankinson SE; Haiman CA; Spiegelman D; Housman DE; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):711-4. PubMed ID: 11401924
[TBL] [Abstract][Full Text] [Related]
36. Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians.
Nowell S; Ratnasinghe DL; Ambrosone CB; Williams S; Teague-Ross T; Trimble L; Runnels G; Carrol A; Green B; Stone A; Johnson D; Greene G; Kadlubar FF; Lang NP
Cancer Epidemiol Biomarkers Prev; 2004 Feb; 13(2):270-6. PubMed ID: 14973106
[TBL] [Abstract][Full Text] [Related]
37. Meat consumption, cooking practices, meat mutagens, and risk of prostate cancer.
John EM; Stern MC; Sinha R; Koo J
Nutr Cancer; 2011; 63(4):525-37. PubMed ID: 21526454
[TBL] [Abstract][Full Text] [Related]
38. Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.
Liu JY; Qu K; Sferruzza AD; Bender RA
Anticancer Drugs; 2007 Jul; 18(6):693-6. PubMed ID: 17762398
[TBL] [Abstract][Full Text] [Related]
39. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M
Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Peer CJ; Sissung TM; Kim A; Jain L; Woo S; Gardner ER; Kirkland CT; Troutman SM; English BC; Richardson ED; Federspiel J; Venzon D; Dahut W; Kohn E; Kummar S; Yarchoan R; Giaccone G; Widemann B; Figg WD
Clin Cancer Res; 2012 Apr; 18(7):2099-107. PubMed ID: 22307138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
